Antioxidant
Antioxidant Therapy with N-acetylcysteine for Neurofibromatosis Type 1
Recruiting0 awardsPhase 2
Cincinnati, Ohio
This trial tests N-Acetyl Cysteine (NAC), a common supplement, to see if it can help children with neurofibromatosis type 1 (NF1) who have cognitive, behavioral, and motor issues. NAC works by reducing harmful substances in the brain, potentially improving behavior and motor skills. NAC is a precursor to glutathione (GSH) and has been studied for its neuroprotective and cognitive benefits in various conditions.
Behavioural Intervention
Educational Letters for Neurofibromatosis
Recruiting1 award
Boston, Massachusetts
This trial aims to compare two educational interventions for individuals with Neurofibromatosis 1 (NF1) to see which one helps more in getting proper health screenings for NF1 patients in regular doctor
Procedure
AI-Enhanced MRI for Detecting Precancerous Lesions in Neurofibromatosis
Recruiting1 award2 criteria
Los Angeles, California
This trial uses a full-body scan and smart computer software to monitor changes in pediatric patients with neurofibromatosis type 1. The MRI takes detailed images, and the AI analyzes them to track any changes over time.
MEK Inhibitor
Trametinib for Cancer With NF1 Genetic Changes
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial tests trametinib, an oral medication, in patients with advanced cancers having an NF1 mutation. Trametinib works by blocking proteins that help cancer cells grow, aiming to stop or slow down the cancer. Trametinib is approved for treating certain types of advanced cancers.
MEK Inhibitor
MEK Inhibitor for Neurofibromatosis
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial tests mirdametinib, a medication taken by mouth, for patients with NF1-related tumors that can't be surgically removed. The drug works by blocking specific proteins to stop or shrink the tumors. Mirdametinib has shown significant and lasting decreases in pain and partial responses in NF1-related plexiform neurofibromas.
Popular Filters
Trials for Neurofibromatosis Patients
Dietary Supplement
Nutraceuticals for Neurofibromatosis
Recruiting1 awardPhase 1
Minneapolis, Minnesota
This trial involves taking curcumin and a special type of olive oil twice a day to help reduce inflammation and oxidative stress. It targets individuals who can tolerate this treatment for an extended period. Curcumin is a natural polyphenol known for its antioxidant and anti-inflammatory properties, and it has been studied in various contexts including metabolic syndrome, diabetes, and exercise-induced oxidative stress.
Behavioural Intervention
Acceptance and Commitment Therapy for Caregivers of Children with Genetic Syndromes
Recruiting1 award8 criteria
Bethesda, Maryland
This trial will test whether Acceptance and Commitment Therapy (ACT) can help caregivers of children with a RASopathy better cope with parenting stress.
MEK1/2 inhibitor
FCN-159 for Neurofibromatosis
Recruiting1 awardPhase 1 & 2
Detroit, Michigan
This trial is testing FCN-159, a new drug taken by mouth, for patients with advanced solid tumors and neurofibromatosis type 1. The drug works by blocking specific proteins that help cancer cells grow. This targeted approach aims to slow down or stop the progression of these diseases.
Kinase Inhibitor
Selumetinib for Plexiform Neurofibromas
Recruiting1 awardPhase 3
Gainesville, Florida
This trial is testing a medication called selumetinib to see if it can help adults with a condition called NF1 who have tumors that cause symptoms and cannot be removed by surgery. The medication works by blocking signals that make the tumors grow.
Trials for NF Patients
Dietary Supplement
Nutraceuticals for Neurofibromatosis
Recruiting1 awardPhase 1
Minneapolis, Minnesota
This trial involves taking curcumin and a special type of olive oil twice a day to help reduce inflammation and oxidative stress. It targets individuals who can tolerate this treatment for an extended period. Curcumin is a natural polyphenol known for its antioxidant and anti-inflammatory properties, and it has been studied in various contexts including metabolic syndrome, diabetes, and exercise-induced oxidative stress.
Behavioural Intervention
Acceptance and Commitment Therapy for Caregivers of Children with Genetic Syndromes
Recruiting1 award8 criteria
Bethesda, Maryland
This trial will test whether Acceptance and Commitment Therapy (ACT) can help caregivers of children with a RASopathy better cope with parenting stress.
MEK1/2 inhibitor
FCN-159 for Neurofibromatosis
Recruiting1 awardPhase 1 & 2
Detroit, Michigan
This trial is testing FCN-159, a new drug taken by mouth, for patients with advanced solid tumors and neurofibromatosis type 1. The drug works by blocking specific proteins that help cancer cells grow. This targeted approach aims to slow down or stop the progression of these diseases.
Kinase Inhibitor
Selumetinib for Plexiform Neurofibromas
Recruiting1 awardPhase 3
Gainesville, Florida
This trial is testing a medication called selumetinib to see if it can help adults with a condition called NF1 who have tumors that cause symptoms and cannot be removed by surgery. The medication works by blocking signals that make the tumors grow.
Trials for NF1 Positive Patients
MEK1/2 inhibitor
FCN-159 for Neurofibromatosis
Recruiting1 awardPhase 1 & 2
Detroit, Michigan
This trial is testing FCN-159, a new drug taken by mouth, for patients with advanced solid tumors and neurofibromatosis type 1. The drug works by blocking specific proteins that help cancer cells grow. This targeted approach aims to slow down or stop the progression of these diseases.
Kinase Inhibitor
Selumetinib for Plexiform Neurofibromas
Recruiting1 awardPhase 3
Gainesville, Florida
This trial is testing a medication called selumetinib to see if it can help adults with a condition called NF1 who have tumors that cause symptoms and cannot be removed by surgery. The medication works by blocking signals that make the tumors grow.
CDK4/6 Inhibitor
Abemaciclib for Neurofibroma
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing a drug, abemaciclib, to see if it can help treat atypical neurofibromas, which are tumors that arise from nerves and can cause serious medical problems. The drug is taken orally, twice daily, in 28-day cycles.
Antioxidant
Antioxidant Therapy for Neurofibromatosis Type 1
Recruiting0 awardsPhase 2
Cincinnati, Ohio
This trial is testing a medication called NAC in children aged 8-16 with a condition called NF1. These children often have problems with movement and behavior, and there is no current treatment for these issues. NAC works by reducing harmful molecules in the brain, which may help improve these symptoms.
Trials With No Placebo
Dietary Supplement
Nutraceuticals for Neurofibromatosis
Recruiting1 awardPhase 1
Minneapolis, Minnesota
This trial involves taking curcumin and a special type of olive oil twice a day to help reduce inflammation and oxidative stress. It targets individuals who can tolerate this treatment for an extended period. Curcumin is a natural polyphenol known for its antioxidant and anti-inflammatory properties, and it has been studied in various contexts including metabolic syndrome, diabetes, and exercise-induced oxidative stress.
Behavioural Intervention
Acceptance and Commitment Therapy for Caregivers of Children with Genetic Syndromes
Recruiting1 award8 criteria
Bethesda, Maryland
This trial will test whether Acceptance and Commitment Therapy (ACT) can help caregivers of children with a RASopathy better cope with parenting stress.
MEK1/2 inhibitor
FCN-159 for Neurofibromatosis
Recruiting1 awardPhase 1 & 2
Detroit, Michigan
This trial is testing FCN-159, a new drug taken by mouth, for patients with advanced solid tumors and neurofibromatosis type 1. The drug works by blocking specific proteins that help cancer cells grow. This targeted approach aims to slow down or stop the progression of these diseases.
CDK4/6 Inhibitor
Abemaciclib for Neurofibroma
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing a drug, abemaciclib, to see if it can help treat atypical neurofibromas, which are tumors that arise from nerves and can cause serious medical problems. The drug is taken orally, twice daily, in 28-day cycles.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.